Headen, Devon M.
Woodward, Kyle B.
Coronel, María M.
Shrestha, Pradeep
Weaver, Jessica D.
Zhao, Hong
Tan, Min
Hunckler, Michael D.
Bowen, William S.
Johnson, Christopher T.
Shea, Lonnie
Yolcu, Esma S.
García, Andrés J. http://orcid.org/0000-0001-6602-2518
Shirwan, Haval http://orcid.org/0000-0002-1657-9470
Article History
Received: 4 February 2017
Accepted: 18 April 2018
First Online: 4 June 2018
Competing interests
: H.S. and E.S.Y. hold equity in FasCure Therapeutics, which has an option to license the SA-FasL technology from the University of Louisville. A patent application (US 62,469,802) titled ‘FasL-engineered biomaterials with immunomodulatory function’, listing A.J.G., H.S., E.S.Y., D.M.H. and H.Z., was submitted on 9 March 2018 by the University of Louisville and Georgia Tech Research Corporation based on the results described in this manuscript.